Physician profile
Shaiful Islam
NPI 1477577526
$1,143.70
in general payments reported to CMS, 2019-2025
15 companies · $83.58 in 2025
The $83.58 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $524 · 2020: $29.63 · 2021: $229 · 2022: $42.38 · 2023: $186 · 2024: $50.09 · 2025: $83.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $319.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $308.10 | 2019-2021 | |
| Abbott Laboratories | $200.17 | 2021-2023 | Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip |
| E.R. Squibb & Sons, L.L.C. | $176.53 | 2019-2025 | Eliquis |
| Novartis Pharmaceuticals Corporation | $92.90 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $63.76 | 2019 | |
| Boston Scientific Corporation | $51.72 | 2019 | |
| Sanofi-Aventis U.S. LLC | $50.36 | 2019 | |
| Pfizer INC. | $44.87 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $36.82 | 2019 | |
| Daiichi Sankyo INC. | $36.11 | 2023 | Injectafer |
| Janssen Scientific Affairs, LLC | $20.65 | 2024 | Xarelto |
| Amgen INC. | $17.47 | 2019 | |
| Lundbeck LLC | $16.34 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.68 | 2024 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $13.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaiful Islam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.